Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment

Contributed Opinion
  ()
With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center. read more >

Canadian Biopharma to Outlicense Pain Drug to South Korean Firm

Research Report
  ()
An Echelon Wealth Partners report discussed the deal terms. read more >

Biopharma's Positive FDA Meeting Outlines Path Forward for Trial

Research Report
  ()
A ROTH Capital Partners note explained the outcome of the tête-a-tête and its implications. read more >

Final Approval of Biopharma's Lead Candidate Both Likely and Imminent

Research Report
  ()
A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication. read more >

Coverage Initiated on Firm with Paradigm-Shifting Colonoscopy Device

Research Report
  ()
A Ladenburg Thalmann report covered the asset, product market and financial projections of this Florida-based company. read more >
News Update

Drug Company Receives $5 Million Milestone Payment

News Update
  ()
Company entitled to receive quarterly earn-out payments from patent agreement. read more >
News Update

Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer's Treatment

News Update
  ()
The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development. read more >

Investor Opportunity Arises from Biopharma's Share Price Weakness on Competitor News

Research Report
  ()
An analyst discussed the implications to this firm of a competitive product's advancement. read more >

Oncology-Focused Biotech Receives Orphan Status for AML Drug

Research Report
  ()
An H.C. Wainwright & Co. report provided an update on two of this company's four product candidates. read more >
News Update

As Nitric Oxide Comes Off Patent, Lower-Cost Options for Life Saving Drug Becoming Possible

  ()
Dr. Ronald Day, a pediatric cardiologist at the University of Utah, has been using nitric oxide to treat children with pulmonary hypertension. Now, with a court ruling invalidating much of a drug patent for nitric oxide, lower-cost options might become available. read more >
Expert Investing Ideas

"PMN anticipates launching its first in-human trial in 2019 of PMN310."

–John Vandermosten, Zacks Small-Cap Research


"DRRX's total revenue for Q2/18 was $3.4M."

–Grant Zeng, Zacks Small-Cap Research


"We consider DRRX a development story."

–Francois Brisebois, Laidlaw & Company


"We are initiating coverage on PMN."

–John Vandermosten, Zacks Small-Cap Research


"DRRX reported its Q1/18, mostly in line with expectations."

–Francois Brisebois, Laidlaw & Company


"PMN is seeking to forge partnerships with big pharmas."

–André Uddin, Mackie Research Capital


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Coverage Initiated on Developer of Brachytherapy Products for Cancer Treatment

Research Report
  ()
H.C. Wainwright & Co. analyst Jason Kolbert provided the rationale for investment in this company. read more >

Medical Device Firm Anticipates Benefit from Patent Ruling

  ()
This company, which develops delivery products for inhaled nitric oxide, a gas used to treat newborns with low oxygen levels and patients with COPD, sees opportunity in a newly invalidated patent. read more >

Medical Device Firm's Clinical Programs Progress in Q2/18

Research Report
  ()
A Ladenburg Thalmann report reviewed the recent financial results for a California-based company that has developed treatments for vaginal laxity and female stress urinary incontinence. read more >

Biotech Marks Progress on Programs for Cancer, Infectious Diseases

Research Report
  ()
This firm, focused on immuno-oncology and infectious diseases including Ebola and Zika, is moving forward on a variety of fronts, according to a Maxim Group analyst. read more >